ArticleNeuropsychology2020
Linear and nonlinear relationships between cognitive subdomains of ability discrepancy and Alzheimer's disease biomarkers.
Article in Neuropsychology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Article
- Rethinking the residual approach: leveraging statistical learning to operationalize cognitive resilience in Alzheimer's disease.Brain informatics · 2025Article
- Rethinking the residual approach: Leveraging machine learning to operationalize cognitive resilience in Alzheimer's disease.medRxiv : the preprint server for health sciences · 2024Article
- Disentangling Accelerated Cognitive Decline from the Normal Aging Process and Unraveling Its Genetic Components: A Neuroimaging-Based Deep Learning Approach.Journal of Alzheimer's disease : JAD · 2024Article
- Cognitive differences across ethnoracial category, socioeconomic status across the Alzheimer's disease spectrum: Can an ability discrepancy score level the playing field?Memory & cognition · 2023Article
- Distinct components of cardiovascular health are linked with age-related differences in cognitive abilities.Scientific reports · 2023Article
- Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage.Current neuropharmacology · 2022Article
- Discrepancy in Fluid and Crystallized Intelligence: An Early Cognitive Marker of Dementia from the LASI-DAD Cohort.Dementia and geriatric cognitive disorders extraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveSubstantial research indicates that fluid and crystallized abilities are highly correlated throughout the adult life span. However, recent proposals suggest that a large discrepancy between these two abilities, defined as crystallized performance minus fluid performance, indicates heightened risk for Alzheimer's disease (AD).
methodIn 266 cognitively healthy older adults, the present study tested linear and quadratic relationships between an ability discrepancy score and early AD neuropathology indexed via in vivo measures of beta-amyloid deposition and cortical thickness in AD-vulnerable regions. We also tested the extent that alternative forms of this ability discrepancy measure (e.g., subdomain discrepancies, verbal-visual discrepancies) and an episodic memory composite might also be sensitive markers of early AD pathology.
resultsAn overall ability discrepancy was linearly and positively correlated with beta- amyloid. A quadratic relationship was found between the overall ability discrepancy score and cortical thickness such that a small positive correlation was found at lower discrepancy levels (fluid > crystallized), but at higher discrepancy levels (crystallized > fluid) a negative relationship was found (i.e., an inverted-U pattern). Similar patterns were found across each subdomain of cognition, but the effects were weaker than the overall ability discrepancy score. Importantly, inclusion of episodic memory (the gold standard) did not alter any of the effects, suggesting that an ability discrepancy confers unique predictiveness of AD biomarkers.
conclusionsThese findings replicate previous findings and increase the confidence in their usefulness to predict AD biomarkers. Longitudinal validation is needed to clearly relate an ability discrepancy to specific stages of preclinical AD. (PsycINFO Database Record (c) 2020 APA, all rights reserved).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.